DEVOTE trial posts positive trial results

Novo Nordisk has announced the full results of the DEVOTE trial investigating the cardiovascular (CV) safety profile of long-acting insulin Tresiba (insulin degludec), in adults with type 2 diabetes (T2D). The trial results, presented at the 77th annual Scientific Sessions of the American Diabetes Association (ADA), also demonstrated a significantly lower rate of severe hypoglycaemia with insulin degludec treatment compared with insulin glargine U1001. These findings, which are the first to specifically examine the CV impact of insulin degludec, provide further evidence to support its safety profile and are in line with previous studies. Dr Ponnusamy Saravanan, Associate Clinical Professor